OliPass Announces Phase 1 Results of 'OLP-1002' at World Congress on Pain

Olipath CEO Jeongsin (center) and Dr. Brian McKittrick (second from left) are explaining the poster presentation to representatives of global pharmaceutical companies. Photo by Olipath.

[Asia Economy Reporter Kwangho Lee] Olipass announced on the 26th that it presented key non-clinical results and the Phase 1 results of the Australian Phase 2a clinical trial for the non-narcotic analgesic 'OLP-1002' as a poster at the '2022 World Congress on Pain.'

The World Congress on Pain is held every two years under the auspices of the International Association for the Study of Pain (IASP). It is described as the largest international conference in the field of pain. This year, it was held in Toronto, Canada, with over 7,000 pain researchers and global pharmaceutical industry representatives participating.

OLP-1002 is an analgesic that acts on 'SCN9A Pre-mRNA' to inhibit the expression of the 'Nav1.7' sodium ion channel. Unlike synthetic drug-based Nav1.7 inhibitors, it has superior selectivity, and strong analgesic efficacy and safety are expected. The goal is to replace narcotic analgesics.

The presentation focused on the analgesic efficacy observed in the recently completed Australian Phase 2a Phase 1 (open-label). By analyzing the animal analgesic efficacy results and clinical efficacy results of OLP-1002, the focus was on explaining the appropriate clinical dose of OLP-1002 confirmed in Phase 2a Phase 1.

In rodent animals, it was confirmed that Nav1.7 inhibition in the central nervous system plays a more important role in pain suppression than in the peripheral nerves. On the other hand, based on the Phase 2a Phase 1 results, it was concluded that strong analgesic efficacy can be secured in humans by inhibiting Nav1.7 only in the peripheral nerves. Jung Olipass, CEO, said, "Since the correlation between the inhibition of Nav1.7 sodium ion channels expressed in peripheral or central nerves and analgesic efficacy was confirmed through the Phase 2a Phase 1 open-label evaluation, the future clinical development of OLP-1002 will proceed smoothly."

Brian McKittrick, Vice President of Olipass, said, "Many Nav1.7 inhibitors have repeatedly failed to secure clinical efficacy due to lack of selectivity," and evaluated, "The confirmation of OLP-1002's excellent clinical efficacy has given strong hope to global industry stakeholders for the development of Nav1.7 analgesics."

The Phase 2a Phase 2 placebo-controlled and double-blind evaluation of OLP-1002 is being conducted at five clinical institutions in Australia. Currently, screening work for patient selection is underway.

This content was produced with the assistance of AI translation services.